4AB.DE लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (7 May 2024 @ 21:05):

Stats
आज की मात्रा	624.00
औसत मात्रा	674.00
बाजार मूल्य	267.46B
EPS	€0 ( 2024-04-26 )
अगली कमाई की तारीख	( €0 ) 2024-07-24
Last Dividend	€1.480 ( 2023-07-13 )
Next Dividend	€0 ( N/A )
P/E	48.54
ATR14	€0.537 (0.36%)

Abbvie Inc सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Abbvie Inc वित्तीय

Annual	2023
राजस्व:	€54.32B
सकल लाभ:	€33.90B (62.42 %)
EPS:	€2.75

FY	2023
राजस्व:	€54.32B
सकल लाभ:	€33.90B (62.42 %)
EPS:	€2.75

FY	2022
राजस्व:	€58.05B
सकल लाभ:	€40.64B (70.00 %)
EPS:	€6.69

FY	2021
राजस्व:	€56.20B
सकल लाभ:	€38.75B (68.96 %)
EPS:	€6.92

Financial Reports:

No articles found.

Abbvie Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€1.410 (N/A)	€1.410 (N/A)	€1.480 (N/A)	€1.480 (N/A)	€1.480 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Abbvie Inc Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 4.84 - low (60.66%) | Divividend Growth Potential Score: 6.92 - Stable (38.37%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.570	2016-07-13
Last Dividend	€1.480	2023-07-13
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	23	--
Total Paid Out	€24.73	--
Avg. Dividend % Per Year	0.00%	--
Score	3.49	--
Div. Sustainability Score	4.84
Div.Growth Potential Score	6.92
Div. Directional Score	5.88	--

Next Divdend (Est)
(2024-07-31)

€0 Estimate 20.17 %

Dividend Stability

0.54 Average

Dividend Score

3.49

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
RNT.F	Ex Dividend Junior	2023-09-13	Annually	0.00%
BIRG.DE	Ex Dividend Junior	2023-05-11	Sporadic	0.00%
ITU.DE	Ex Dividend Knight	2023-10-06	Quarterly	0.00%
TNE5.DE	Ex Dividend Junior	2023-12-12	Semi-Annually	0.00%
CSH.DE	Ex Dividend Junior	2023-05-18	Annually	0.00%
MBB.DE	Ex Dividend Junior	2023-06-13	Annually	0.00%
WIB.DE	Ex Dividend Knight	2023-05-09	Annually	0.00%
ENI.DE	Ex Dividend Knight	2023-11-20	Semi-Annually	0.00%
OPC.DE	Ex Dividend Knight	2023-09-07	Quarterly	0.00%
ADM.DE	Ex Dividend Knight	2023-08-15	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.110	1.500	7.80	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.524	1.500	5.28	7.93	[0.1 - 1]
payoutRatioTTM	1.315	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	8.88	1.000	7.82	7.82	[3 - 30]
operatingCashFlowPerShareTTM	10.49	2.00	6.50	10.00	[0 - 30]
freeCashFlowPerShareTTM	10.15	2.00	4.93	9.85	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.624	1.000	2.93	2.93	[0.2 - 0.8]
operatingProfitMarginTTM	0.247	1.000	7.06	7.06	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.84

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	47.98	1.000	5.25	0	[1 - 100]
returnOnEquityTTM	0.524	2.50	6.97	7.93	[0.1 - 1.5]
freeCashFlowPerShareTTM	10.15	2.00	6.62	9.85	[0 - 30]
dividendYielPercentageTTM	3.75	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	10.49	2.00	6.50	10.00	[0 - 30]
payoutRatioTTM	1.315	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	18.18	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.343	1.000	3.93	0	[0.1 - 0.5]
Total Score				6.92

Abbvie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.